I'm bullish on Harrow due to the VEVYE Access for All program, which makes dry eye treatment affordable and drives strong prescription growth. VEVYE's discounted pricing addresses a massive, ...
Investors considering a purchase of Harrow Inc (Symbol: HROW) stock, but tentative about paying the going market price of $35.48/share, might benefit from considering selling puts among the ...
Harrow is a company focused on eye health with a strong distribution platform and CEO ownership. Q3 earnings were below expectations, and guidance was lowered, raising concerns about operational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results